Nutriband Chairman to Present AVERSA Technology at NobleCon21 Investor Conference

Nutriband Inc. Chairman and Co-Founder Serguei Melnik will present at NobleCon21, Noble Capital Markets' annual emerging growth equity conference, on December 3 at Florida Atlantic University's Executive Education Complex in Boca Raton, Florida. The presentation offers investors insight into the company's technology platform and business strategy, with a discounted attendance rate available using code NTRBNOBLECON. For those unable to attend in person, a high-definition webcast will be available the following day at https://nobleconference.com and https://Channelchek.com, where it will remain archived for 90 days.

The company's presentation gains significance from its focus on developing transdermal pharmaceutical products, particularly its lead product: an abuse-deterrent fentanyl patch incorporating proprietary AVERSA technology. This technology represents a substantial advancement in transdermal drug delivery systems, specifically designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The timing is critical as opioid abuse continues to be a serious public health concern both in the United States and globally, making technological solutions increasingly valuable.

AVERSA technology's broad application potential allows it to be incorporated into any transdermal patch, creating opportunities across multiple pharmaceutical products that carry abuse risks. This versatility enhances the technology's commercial prospects and addresses a growing market need for safer drug delivery systems. The full press release detailing the announcement can be viewed at https://nnw.fm/Bx5x3, providing additional context about the company's strategic direction.

Emerging growth equity conferences like NobleCon21 serve as important venues for companies to communicate their value proposition directly to potential investors and financial analysts. For Nutriband, this presentation represents an opportunity to showcase how its technology platform addresses both medical needs and market opportunities in the pharmaceutical sector. Investors following Nutriband can access the latest news and updates relating to NTRB in the company's newsroom at https://nnw.fm/NTRB, though the company notes that any material contained in or derived from its websites is not part of the official press release.

The company maintains its corporate website at https://www.nutriband.com, which serves as an additional resource for information about its operations and technology development. As pharmaceutical companies face increasing pressure to develop safer drug delivery methods, technologies like AVERSA that specifically target abuse prevention gain strategic importance. The presentation at NobleCon21 allows Nutriband to position itself within this evolving landscape while engaging with the investment community about its growth potential and technological advantages in transdermal drug delivery systems.